International Journal of Medical Sciences

Impact factor

17 November 2018

ISSN 1449-1907 News feeds of published articles

Manuscript login | Account

open access Global reach, higher impact

Journal of Genomics in PubMed Central. Submit manuscript now...


Journal of Cancer

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)


Journal of Biomedicine


PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2008; 5(5):244-247. doi:10.7150/ijms.5.244

Research Paper

Acceptability of cancer chemoprevention trials: impact of the design

Anne-Sophie Maisonneuve1, 2, Laetitia Huiart1, 2, Laetitia Rabayrol1, 2, Doug Horsman3, Remi Didelot4, Hagay Sobol1, 2, Francois Eisinger1, 2, 3 ✉

1. Institut Paoli-Calmettes, Department of Oncogenetics Prevention and Screening Marseille France (FE, ASM, LH, LR, HS)
2. INSERM U 599, Marseille France (FE, ASM, LH, LR, HS)
3. Hereditary Cancer Program British Colombia Cancer Agency (FE, DH)
4. Local Administration of the National Health Insurance System – “Centre d'Examen de Sante (CESAM 13) ” Marseille France (RD)


Background: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials.

Methods: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials.

Results: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) were far less acceptable: 9.2% for lung cancer (OR=7.7 CI95% 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI95% 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI95% 3.6-12.9).

Conclusion: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate.

Keywords: Research Design, Randomized Controlled Trials, Behavior, Attitude, Preventive Health Services, Prevention & Control, Neoplasms, Breast, Lung

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
How to cite this article:
Maisonneuve AS, Huiart L, Rabayrol L, Horsman D, Didelot R, Sobol H, Eisinger F. Acceptability of cancer chemoprevention trials: impact of the design. Int J Med Sci 2008; 5(5):244-247. doi:10.7150/ijms.5.244. Available from